The Irish company Cosmo Pharmaceuticals has published promising results for its Clascoterone 5% hair loss treatment. In two Phase 3 clinical trials, conducted with 1,465 patients in the United States and Europe (Scalp 1 and Scalp 2), the product demonstrated significantly greater efficacy than a placebo: +539% in the first study and +168% in the second.
According to Dr. Maria Hordinsky, Professor of Dermatology at the University of Minnesota, this data marks a significant milestone. Until now, patients only had access to limited solutions or those with risks associated with systemic hormonal exposure.
A novel mechanism
Clascoterone 5% acts directly on hair follicle receptors by blocking dihydrotestosterone (DHT), a key hormone in male pattern baldness. Unlike oral treatments, it does not lead to systemic absorption and precisely targets the biological cause of androgenetic alopecia.
This product thus becomes the first topical androgen receptor inhibitor designed for male pattern baldness, which affects more than one billion men worldwide.
Next step
Cosmo Pharmaceuticals will continue monitoring patients until spring 2026 to confirm the treatment's safety before submitting applications for authorization to the US and European regulatory authorities.
 Sophie de Duiéry
|
09/12/2025 | 
Anglais
Français
Español
Italien
Português